Search 

Sinovant Sciences (http://www.sinovant.com) is an innovative biopharmaceutical company based in Shanghai, Beijing and Hong Kong. Sinovant was founded by Chinese scientists and physicians, including Chinese “Returnees”. Sinovant is uniquely positioned to bring cutting-edge global medical innovation to China, and transformative Chinese medical innovation to the world.  

   

Sinovant has a diverse pipeline of 11 investigational products in development, among which 5 drug candidates are in phase III or beyond. Our products span over 6 therapeutic areas including oncology, infectious disease, urology / nephrology, gastrointestinal diseases, dermatology and rare diseases. 

Global medical device company focused on oncology and interventional therapy.

Sixty Degree Capital Inc. is a Toronto based venture capital investor with US$200MM+ under management investing across North America and Asia. We are dedicated to building strong, long-term relationships with our partners and investors within our industries of focus. Our Toronto office has been actively investing in Healthcare related sectors in the past several years. By partnering with top tier lead investors such as Lumira Ventures, Versant Ventures, Google Ventures, iNovia Capital etc., we have deployed our capital into some exciting North American companies including Schrödinger (Drug discovery platform), Turnstone Biologics and Northern Biologics (Immuno Oncology therapeutics), as well as Antios Therapeutics (HBV innovative therapy). As a growth to late stage investor, our initial cheque size ranges from USD 3 to 5m with reserve of USD 10~20m.

Alternative protein with microalgae

Sotera Health is driven by its mission, Safeguarding Global Health®. Along with our three best-in-class businesses – Sterigenics®, Nordion®and Nelson Labs®– we are a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry.

Approximately 900,000 people annually in the United States suffer from damage to the articular cartilage and subchondral bone, with the knee being the most commonly affected. Articular cartilage lesions have a limited intrinsic ability to heal and often result in osteoarthritis (OA). Progression to OA poses significant economic burden for the United States, totaling over $300 billion annually, and negatively impacting 54.4 million adults (23% of the population). Current strategies for cartilage restoration include bone marrow stimulation (microfracture) and autologous chondrocyte implantation (ACI). These methods have high failure rates (25-50% at 10 years), prolonged rehabilitation times (> 12 months), and show decreasing efficacy in patients older than 40-50 years of age. 

Sparta Biomedical is developing the first-of-its kind osteochondral repair technology (SBM-01) for support the restoration of the cartilage-bone unit. This purpose-built technology is comprised of a novel biomimetic material possesses cartilage-like properties-- tension, compression, tribology, and fatigue.  The patent-pending surface is combined with a uniquely designed base to promote efficient osseous attachment and stable fixation over the long-term. Sparta’s technology will be a significant advancement in the current surgical standard of care. It will result in substantial pain reduction, immediate weight bearing post-operatively, and full range ambulation.

Sparta has assembled a nationally recognized team of scientists, clinicians, orthopedic regulatory experts to develop SBM-01 rapidly and cost effectively. SBM-01's risk profile enables an efficient regulatory path. Furthermore, it is well positioned to obtain Breakthrough Device Designation from the US FDA.

hospital